BTAI (BioXcel Therapeutics) EBIT: $-58.15 Mil (TTM As of Mar. 2026)


BTAI BioXcel Therapeutics Inc BTAI
14 GF Score
Price $1.32
GF Value $0.67
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is BioXcel Therapeutics EBIT?

BioXcel Therapeutics BTAI -0.38% 14 EBIT is $-58.15 Mil as of Mar. 2026. GuruFocus rates BTAI with a GF Score™ of 14/100 and a GF Value™ of $0.67 (Significantly Overvalued). The stock has 6 warning signs investors should review.

BioXcel Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-8.49 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-58.15 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioXcel Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -121.49%. BioXcel Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -19,524.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioXcel Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -46.94%.

BioXcel Therapeutics  (NAS:BTAI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioXcel Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-40.892 * ( 1 - 0% )/( (35.011 + 32.309)/ 2 )
=-40.892/33.66
=-121.49 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=44.916 - 19.146 - ( 28.415 - max(0, 53.926 - 44.685+28.415))
=35.011

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=34.025 - 22.802 - ( 17.18 - max(0, 54.994 - 33.908+17.18))
=32.309

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

BioXcel Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-33.972/( ( (0.231 + max(-12.66, 0)) + (0.117 + max(-15.835, 0)) )/ 2 )
=-33.972/( ( 0.231 + 0.117 )/ 2 )
=-33.972/0.174
=-19,524.14 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.233 + 0.722 + 15.315) - (19.146 + 0 + 9.784)
=-12.66

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.216 + 0.5 + 16.012) - (22.802 + 0 + 9.761)
=-15.835

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioXcel Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-58.145/123.869
=-46.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioXcel Therapeutics EBIT Related Terms

BioXcel Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for BioXcel Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioXcel Therapeutics EBIT Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -106.89 -157.54 -165.74 -44.47 -52.91

BioXcel Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.26 -14.97 -26.54 -8.15 -8.49

BTAI vs HYEX, CPHI, ZYBT: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioXcel Therapeutics EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's EV-to-EBIT falls into.


BTAI
14GF Score
BioXcel Therapeutics Inc BTAI
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioXcel Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-58.15 Mil mean?
BioXcel Therapeutics (BTAI) has a EBIT of $-58.15 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioXcel Therapeutics.
Is BioXcel Therapeutics' EBIT too high?
BioXcel Therapeutics' current EBIT is $-58.15 Mil. Overall, BioXcel Therapeutics has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' EBIT compare to HYEX and CPHI?
BioXcel Therapeutics' EBIT of $-58.15 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioXcel Therapeutics. BioXcel Therapeutics's current EBIT is $-58.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $1.32 — trading 97% above its estimated fair value. The current EBIT is $-58.15 Mil. BioXcel Therapeutics' overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current EBIT is $-58.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioXcel Therapeutics (BTAI) Overvalued in 2026?

Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued. The current stock price of $1.32 is trading 97% above its estimated GF Value™ of $0.67. GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.

Key valuation signals for BTAI:

  • EBIT: $-58.15 Mil
  • GF Value™: $0.67 vs. price of $1.32 (97% above fair value)
  • GF Score™: 14/100 with 6 warning signs

No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioXcel Therapeutics Business Description

Other Exchanges BX20:Germany
Address 555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
14GF Score

Get the complete analysis for BTAI

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price
$0.67
GF Value